Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia
- 141 Downloads
Platelet-lowering agents currently often used in essential thrombocythemia (ET) patients with a high risk of developing thrombohemorrhagic complications include hydroxyurea, interferon-alpha, and anagrelide . Anagrelide is a very effective drug for controlling peripheral blood platelet counts and symptoms in most patients with thrombocythemia . However, anagrelide therapy is not recommended for women who are pregnant [3, 4]. Nevertheless, there is no clear evidence of anagrelide having an adverse influence on pregnancy in humans.
This report describes our experience with anagrelide administration during pregnancy. A 26-year-old woman was diagnosed with ET in July 2000. The first manifestation of ET in this woman was severe thrombosis of the cerebral venous sinuses. Thrombocytosis (948×109/l) was not the single risk factor for thrombosis. Hereditary thrombophilia was also diagnosed. Our patient is a heterozygous carrier of the factor V Leiden mutation.
Treatment of ET with...
KeywordsThrombophilia Essential Thrombocythemia Anagrelide Factor Versus Leiden Mutation Thrombocyte Count
- 1.Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJJ, Brière J, Kiladjan JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbach H, Cervantes F, Reilly JT, Demory J-L, Gisslinger H, Guardiola P, Martyré MC, Le Bousse-Kerdilès MC, Thiele J (1999) Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med 54:46–62CrossRefPubMedGoogle Scholar
- 3.Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89:215–232PubMedGoogle Scholar